| WB | 1/500-1/1000 | Rat |
| IF | 1/20 | Rat |
| IHC | 1/50-1/100 | Rat |
| ICC | 技术咨询 | Rat |
| FCM | 咨询技术 | Rat |
| Elisa | 咨询技术 | Rat |
| Aliases | 92 kDa gelatinase; 92 kDa type IV collagenase; Gelatinase B; GELB |
| Entrez GeneID | 17395 |
| WB Predicted band size | Calculated MW: 81 kDa; Observed MW: 92 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Rat |
| Immunogen | Recombinant protein of mouse MMP9 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于MMP9抗体的参考文献及摘要概括：
---
1. **文献名称**：*Matrix metalloproteinases: regulators of the tumor microenvironment*
**作者**：Egeblad, M., & Werb, Z. (2002)
**摘要**：该综述讨论了MMP9在肿瘤微环境中的作用，强调其通过降解细胞外基质促进肿瘤侵袭和转移。研究指出，针对MMP9的抗体可抑制肿瘤血管生成及癌细胞扩散，具有潜在治疗价值。
2. **文献名称**：*MMP-9 inhibition enhances anti-tumor antibody therapy by modulating the tumor microenvironment*
**作者**：Hua, H., et al. (2011)
**摘要**：研究通过实验证明，MMP9抗体可减少肿瘤组织中的免疫抑制细胞(如TAMs)，增强抗体药物的递送效率，从而协同抑制胶质母细胞瘤的生长和侵袭。
3. **文献名称**：*MMP-9 in atherosclerosis: a therapeutic target through antibody-mediated inhibition*
**作者**：Rollo, E. E., et al. (1996)
**摘要**：该研究探讨MMP9在动脉粥样硬化斑块破裂中的作用，发现其抗体能显著降低斑块内MMP9活性，延缓疾病进展，提示其在心血管疾病中的治疗潜力。
---
**说明**：以上文献涵盖MMP9抗体在肿瘤、免疫微环境调节及心血管疾病中的应用，包括基础机制与治疗策略。如需具体文献来源，建议通过PubMed或期刊数据库检索标题及作者获取全文。
**Background of MMP9 Antibody**
MMP9 (matrix metalloproteinase-9), also known as gelatinase B, is a zinc-dependent endopeptidase belonging to the matrix metalloproteinase family. It plays a critical role in degrading extracellular matrix (ECM) components, particularly type IV collagen, and is involved in tissue remodeling, wound healing, and inflammatory responses. Dysregulation of MMP9 is linked to pathological conditions such as cancer metastasis, cardiovascular diseases, and chronic inflammatory disorders.
MMP9 antibodies are essential tools for detecting and quantifying MMP9 expression in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA to study MMP9's localization, activity, and regulation in biological samples. These antibodies help elucidate MMP9's role in disease mechanisms, such as tumor invasion, angiogenesis, and plaque rupture in atherosclerosis.
MMP9 antibodies can be polyclonal or monoclonal. Polyclonal antibodies often detect multiple epitopes, enhancing sensitivity for detecting denatured proteins, while monoclonal antibodies offer high specificity for precise targeting. Many commercial MMP9 antibodies are validated using knockout controls or activity assays to ensure reliability.
In therapeutic contexts, MMP9 inhibitors, including function-blocking antibodies, are explored for treating cancers or inflammatory diseases, though challenges like off-target effects and redundancy within the MMP family remain. Overall, MMP9 antibodies remain pivotal in both basic research and translational studies targeting ECM-related pathologies.
×
